--- title: "James T. Brunz, MD Recognized by Abbott Neuromodulation as a Spinal Cord Stimulation Center of Excellence Physician" type: "News" locale: "en" url: "https://longbridge.com/en/news/296792290.md" description: "In Tea, South Dakota on August 24, 2026, Dr. James T. Brunz, a specialist in interventional spine and pain management at Orthopedic Institute (OI), has been acknowledged by Abbott Neuromodulation as a leading physician in Spinal Cord Stimulation (SCS). Dr. Brunz earns this recognition due to his extensive expertise and successful clinical practice in the field." datetime: "2026-08-24T12:44:29.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296792290.md) - [en](https://longbridge.com/en/news/296792290.md) - [zh-HK](https://longbridge.com/zh-HK/news/296792290.md) generator: "portal-rs" --- # James T. Brunz, MD Recognized by Abbott Neuromodulation as a Spinal Cord Stimulation Center of Excellence Physician In Tea, South Dakota on August 24, 2026, Dr. James T. Brunz, a specialist in interventional spine and pain management at Orthopedic Institute (OI), has been acknowledged by Abbott Neuromodulation as a leading physician in Spinal Cord Stimulation (SCS). Dr. Brunz earns this recognition due to his extensive expertise and successful clinical practice in the field. ### Related Stocks - [ABT.US](https://longbridge.com/en/quote/ABT.US.md) ## Related News & Research - [Xcel Wealth Management LLC Cuts Stock Holdings in Abbott Laboratories $ABT](https://longbridge.com/en/news/296700328.md) - [Murphy Pohlad Asset Management LLC Purchases 12,140 Shares of Abbott Laboratories $ABT](https://longbridge.com/en/news/296461096.md) - [Did Abbott’s Q2 Beat and Profit Hike Just Shift Abbott Laboratories’ (ABT) Investment Narrative?](https://longbridge.com/en/news/296546525.md) - [Abbott agrees to $670 million settlement of infant formula cases](https://longbridge.com/en/news/296534956.md) - [Abbott settles appeal over $495 million infant formula verdict](https://longbridge.com/en/news/296386129.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**